Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB2 | O60825 | 2/20 | 0.37 |
| ▸ | PFKFB1 | P16118 | 2/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 9/20 | 0.34 |
| ▸ | CFD | P00746 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236948 | 0.85 | PFKFB2 (0.41) | PFKFB2PFKFB1PFKFB3CSNK2A2CSNK2A1 | |
| SCHEMBL19208547 | 0.84 | CFD (0.38) | CFDMAPTKDM4EALDH1A1 | |
| SCHEMBL17023819 | 0.83 | CFD (0.41) | CFDMAPT | |
| SCHEMBL25925070 | 0.83 | POLB (0.47) | PFKFB2PFKFB1PFKFB3ARCFD | |
| SCHEMBL18649190 | 0.82 | CFD (0.35) | CFDMAPTKDM4EALDH1A1 | |
| SCHEMBL15542673 | 0.80 | ELANE (0.39) | PFKFB2PFKFB1PFKFB3ARMAPT | |
| SCHEMBL15541589 | 0.80 | HTR6 (0.39) | PFKFB2PFKFB1PFKFB3ARMAPT | |
| SCHEMBL19208697 | 0.79 | MAPT (0.48) | PFKFB2PFKFB1PFKFB3ARMAPT | |
| SCHEMBL15541536 | 0.79 | AR (0.44) | PFKFB2PFKFB1PFKFB3ARMAPT | |
| SCHEMBL19208493 | 0.79 | SMN1; SMN2 (0.45) | PFKFB2PFKFB1PFKFB3ARMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3925956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BioCryst Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3411411-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3411411-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | Biocryst Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | PFKFB2 1204/4885PFKFB1 1031/4885PFKFB3 1297/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | PFKFB2 1327/4885PFKFB1 1028/4885PFKFB3 1106/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | PFKFB2 3240/4885PFKFB1 2704/4885PFKFB3 3094/4885 |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | C9, C5, C1QBP | PFKFB2 1327/4885PFKFB1 1028/4885PFKFB3 1106/4885 |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | PFKFB2 1327/4885PFKFB1 1028/4885PFKFB3 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.